1. Home
  2. WAY vs GH Comparison

WAY vs GH Comparison

Compare WAY & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Waystar Holding Corp.

WAY

Waystar Holding Corp.

HOLD

Current Price

$24.86

Market Cap

4.8B

Sector

N/A

ML Signal

HOLD

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$88.76

Market Cap

13.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WAY
GH
Founded
1999
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
13.3B
IPO Year
2023
2018

Fundamental Metrics

Financial Performance
Metric
WAY
GH
Price
$24.86
$88.76
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
16
20
Target Price
$37.56
$117.80
AVG Volume (30 Days)
2.6M
1.6M
Earning Date
05-20-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
569.23
6.74
EPS
0.61
N/A
Revenue
$1,099,278,000.00
$982,021,000.00
Revenue This Year
$18.35
$33.40
Revenue Next Year
$10.53
$28.55
P/E Ratio
$40.66
N/A
Revenue Growth
16.50
32.88
52 Week Low
$21.13
$36.36
52 Week High
$41.96
$120.74

Technical Indicators

Market Signals
Indicator
WAY
GH
Relative Strength Index (RSI) 44.83 38.42
Support Level $21.13 $54.39
Resistance Level $26.29 $103.16
Average True Range (ATR) 1.08 3.90
MACD 0.02 -0.28
Stochastic Oscillator 25.24 39.48

Price Performance

Historical Comparison
WAY
GH

About WAY Waystar Holding Corp.

Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. Its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for solutions extends throughout the United States and includes Puerto Rico and other USA Territories.

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: